FDA 483 - Embecta Medical 1, LLC. - October 17, 2025

During an FDA inspection conducted from October 15-17, 2025, Embecta Medical 1, LLC., a manufacturer in Holdrege, NE, received observations highlighting significant deficiencies in their quality control for drug components. The inspection report, known as an FDA Form 483, detailed two main issues. First, the firm accepted supplier reports for components, including a bulk ingredient for antiseptic swabs, without performing essential identity tests or adequately validating supplier analyses. Specifically, their internal identification tests were not shown to meet recognized standards, and a key drug component supplier was not registered with the FDA, a fact Embecta Medical failed to verify during supplier re-qualification.

Second, the firm's laboratory controls were deemed insufficient, lacking scientifically sound specifications to ensure component quality and purity. They did not test a raw material for volatile and unspecified impurities as required by its established monograph. This deficiency is particularly concerning given a prior FDA warning letter issued to one of their suppliers regarding inadequate cleaning processes for chemical blending. These observations, issued under the Federal Food, Drug, and Cosmetic Act, indicate Embecta Medical must implement comprehensive corrective actions to enhance component testing, validate supplier reliability, and establish robust laboratory controls to guarantee the identity, strength, quality, and purity of materials used in their drug products.